Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan Dual Therapy vs Standard Triple Therapy for H. Pylori Eradication
NCT04901663Phase 4
Key facts
- Status
- Completed
- Start
- Jun 2021
- Primary completion
- Aug 2021
- Countries
- 1
- Sponsor
- Dow University of Health Sciences
- Modality
- Small Molecules
- Drugs
- vonoprazan
- Conditions
- Helicobacter pylori infection
01
Overview
Phase 4, randomised, open-label trial of vonoprazan in Helicobacter pylori infection (2 arms), sponsored by Dow University of Health Sciences. Primary endpoint: Helicobacter Pylori Eradication at 4 weeks. Started Jun 2021; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Omeprazole Group
Omeprazole 20 mg BD + Amoxicillin 1000 mg BD + Clarithromycin 500 mg BD
Vonoprazan Group
Vonoprazan 20 mg BD + Amoxicillin 1000 mg BD
03
Who it enrols
Patients with confirmed Helicobacter Pylori infection, excluding those with previous stomach surgery, recent antibiotic/PPI/steroid/NSAID use, pregnancy/lactation, substance abuse, or severe neurological/psychiatric disorders.
04
Endpoints
Primary
Helicobacter Pylori Eradication
Beyond the preview
Go deeper on NCT04901663.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901663.